153 related articles for article (PubMed ID: 38443321)
1. HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls.
Zhang H; Finkelman BS; Ettel MG; Velez MJ; Turner BM; Hicks DG
Histopathology; 2024 Jul; 85(1):3-19. PubMed ID: 38443321
[TBL] [Abstract][Full Text] [Related]
2. Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?
Rakha EA; Pigera M; Shin SJ; D'Alfonso T; Ellis IO; Lee AH
Histopathology; 2016 Jul; 69(1):20-4. PubMed ID: 26542743
[TBL] [Abstract][Full Text] [Related]
3. The evolving role of HER2 evaluation for diagnosis and clinical decision making for breast and gastric adenocarcinoma.
Hicks DG; Whitney-Miller CL
Biotech Histochem; 2013 May; 88(3-4):121-31. PubMed ID: 23293935
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients.
Dodson A; Parry S; Ibrahim M; Bartlett JM; Pinder S; Dowsett M; Miller K
J Pathol Clin Res; 2018 Oct; 4(4):262-273. PubMed ID: 30066480
[TBL] [Abstract][Full Text] [Related]
5. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.
Kunz PL; Mojtahed A; Fisher GA; Ford JM; Chang DT; Balise RR; Bangs CD; Cherry AM; Pai RK
Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):13-24. PubMed ID: 21617522
[TBL] [Abstract][Full Text] [Related]
6. Equivocal (HER2 IHC 2+) breast carcinomas: gene-protein assay testing reveals association between genetic heterogeneity, individual cell amplification status and potential treatment benefits.
Pekar G; Kasselaki I; Pekar-Lukacs A; Dekany C; Hellberg D; Tot T
Histopathology; 2019 Jan; 74(2):300-310. PubMed ID: 30113715
[TBL] [Abstract][Full Text] [Related]
7. The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma.
Talia KL; Banet N; Buza N
Pathology; 2023 Feb; 55(1):8-18. PubMed ID: 36503635
[TBL] [Abstract][Full Text] [Related]
8. Unusual Patterns of HER2 Expression in Breast Cancer: Insights and Perspectives.
Grassini D; Cascardi E; Sarotto I; Annaratone L; Sapino A; Berrino E; Marchiò C
Pathobiology; 2022; 89(5):278-296. PubMed ID: 35500561
[TBL] [Abstract][Full Text] [Related]
9. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
10. HER2 testing in gastric and gastroesophageal adenocarcinomas.
Vakiani E
Adv Anat Pathol; 2015 May; 22(3):194-201. PubMed ID: 25844677
[TBL] [Abstract][Full Text] [Related]
11. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
[TBL] [Abstract][Full Text] [Related]
12. Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization.
Vogel UF
Diagn Pathol; 2010 Jul; 5():50. PubMed ID: 20670419
[TBL] [Abstract][Full Text] [Related]
13. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
Bartley AN; Washington MK; Ventura CB; Ismaila N; Colasacco C; Benson AB; Carrato A; Gulley ML; Jain D; Kakar S; Mackay HJ; Streutker C; Tang L; Troxell M; Ajani JA
Arch Pathol Lab Med; 2016 Dec; 140(12):1345-1363. PubMed ID: 27841667
[TBL] [Abstract][Full Text] [Related]
14. HER-2 overexpression in female genital tract clear cell carcinomas: Evaluation of different scoring guidelines, clinicopathological features and prognostic impact.
Edjtemaei R; Nili F; Jahanzad I; Ameli F; Ghasemi D
Ann Diagn Pathol; 2023 Oct; 66():152184. PubMed ID: 37543027
[TBL] [Abstract][Full Text] [Related]
15. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
[TBL] [Abstract][Full Text] [Related]
16.
Bensch F; Brouwers AH; Lub-de Hooge MN; de Jong JR; van der Vegt B; Sleijfer S; de Vries EGE; Schröder CP
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2300-2306. PubMed ID: 30058029
[TBL] [Abstract][Full Text] [Related]
17. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
[TBL] [Abstract][Full Text] [Related]
18. Current Laboratory Testing Practices for Assessment of ERBB2/HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma.
Hagemann IS; Bridge JA; Tafe LJ; Hameed MR; Moncur JT; Bellizzi AM; Dolan M; Vasalos P; Kane ME; Souers RJ; Yemelyanova A
Arch Pathol Lab Med; 2023 Oct; 147(10):1148-1157. PubMed ID: 36538387
[TBL] [Abstract][Full Text] [Related]
19. HER2 testing in breast carcinoma: very low concordance rate between reference and local laboratories in Brazil.
Wludarski SC; Lopes LF; Berto E Silva TR; Carvalho FM; Weiss LM; Bacchi CE
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):112-8. PubMed ID: 20930616
[TBL] [Abstract][Full Text] [Related]
20. The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer.
Griffin N; Marsland M; Roselli S; Oldmeadow C; Attia J; Walker MM; Hondermarck H; Faulkner S
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32957504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
